Abstract
To combat viral pandemics, there is an urgent need for inexpensive new technologies that enable fast, reliable, and scalable detection of viruses. Here we repurposed the type III CRISPR-Cas system for sensitive and sequence specific detection of SARS-CoV-2 in an assay that can be performed in one hour or less. RNA recognition by type III systems triggers Cas10-mediated polymerase activity, which simultaneously generates pyrophosphates, protons and cyclic oligonucleotides. We show that amplified products of the Cas10-polymerase are detectable using colorimetric or fluorometric readouts.
Competing Interest Statement
B.W. is the founder of SurGene, LLC, and VIRIS Detection Systems Inc.. B.W., A.S.-F., A. Nemudraia and A. Nemudryi are inventors on patent applications related to CRISPR-Cas systems and applications thereof.
Funding Statement
We are grateful to members of Bozeman Health that provided deidentified patient samples. Specifically, Christopher Nero, Douglas Smoot, Winfield Wallace, Cayley Faurot-Daniels, Verena Lawrence and Melissa Blauvelt. We are also grateful to Michelle Flenniken, Katie Daughenbaugh, Diane Bimczok and other members of the COVID task force at MSU for assistance establishing the COVID testing center. A.S.-F. is a postdoctoral fellow of the Life Science Research Foundation, which is supported by the Simons Foundation. A.S.-F. is supported by the Postdoctoral Enrichment Program Award from the Burroughs Wellcome Fund. Research in the Wiedenheft lab and the biosafety level 3 facility is supported by the office of the Vice President for Research at Montana State University, and a sponsored research agreement from VIRIS Detection Systems Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Suspect cases of COVID-19 were tested in a CLIA lab and instructed to self-quarantine until notified of the RT-qPCR test results. All laboratory confirmed positive cases of COVID-19 were contacted via telephone by local public health nurses to complete contact tracing. During this interview, the nurses collected recorded symptoms, symptom onset date, travel history, contact with other known laboratory confirmed cases, close contacts and activities on the two days before symptom onset up until notification of a positive test. Data collection was conducted as part of a public health response. Information on COVID-19 patients COVID-19 (gender, age, disease severity, etc) is not available. The study was reviewed by the Montana State University Institutional Review Board (IRB) For the Protection of Human Subjects (FWA 00000165) and was exempt from IRB oversight in accordance with Code of Federal regulations, Part 46, section 101. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data shown in the manuscript are available upon request from the corresponding author. Expression plasmids are available upon request. SARS-CoV-2 genomes were accessed on the GISAID database website (https://www.gisaid.org/).
